Profound Medical Corp.

Toronto Stock Exchange PRN.TO

Profound Medical Corp. Shareholders' Equity for the year ending December 31, 2023: USD 31.18 M

Profound Medical Corp. Shareholders' Equity is USD 31.18 M for the year ending December 31, 2023, a -40.04% change year over year. Shareholders' equity are the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim.

Profound Medical Corp. Shareholders' Equity for the year ending December 31, 2022 was USD 52.00 M, a -35.49% change year over year.
Profound Medical Corp. Shareholders' Equity for the year ending December 31, 2021 was USD 80.62 M, a -17.19% change year over year.
Profound Medical Corp. Shareholders' Equity for the year ending December 31, 2020 was USD 97.35 M, a 785.52% change year over year.
Profound Medical Corp. Shareholders' Equity for the year ending December 31, 2019 was USD 10.99 M, a -23.26% change year over year.

Key data

Date	Shareholders' Equity	Minority Interest	Total Equity	Total Stockholders Equity and Liabilities

Toronto Stock Exchange: PRN.TO

Profound Medical Corp.

CEO	Dr. Arun Swarup Menawat MBA, Ph.D.
IPO Date	July 10, 2018
Location	Canada
Headquarters	2400 Skymark Avenue
Employees	131
Sector	Healthcare
Industries Medical Instruments 3D Printing Biotechnology Clinical Trials Dental Care Drugstores & Retail Pharmacies Pharmaceuticals Telehealth

Description

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system used for magnetic resonance imaging scanner in hospitals and treatment facilities. The company also offers Sonalleve, a therapeutic platform for the treatment of uterine fibroids and palliative pain relief associated with metastases in bone, as well as non-invasive treatment of uterine fibroids. Profound Medical Corp. is headquartered in Mississauga, Canada.

Key trends

Past 5 years